The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ACTIVISION BLIZZARD INC | COM | 00507V109 | BBG000CVWGS6 | 910,440 | 10,800 | SH | SOLE | 10,800 | 0 | 0 | ||
| AKERO THERAPEUTICS INC | COM | 00973Y108 | BBG00L9211Y8 | 75,723,196 | 1,621,829 | SH | SOLE | 1,621,829 | 0 | 0 | ||
| SPDR SER TR | S&P BIOTECH | 78464A870 | BBG000MQQ963 | 140,275 | 1,686 | SH | SOLE | 1,686 | 0 | 0 | ||
| STOKE THERAPEUTICS INC | COM | 86150R107 | BBG00JPCBPG9 | 153,536,329 | 14,443,681 | SH | SOLE | 14,443,681 | 0 | 0 | ||